Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae

Vaccine

Volumn 26, Issue 35, 2008, Pages 4434-4445

  Trotter, Caroline L ^a   McVernon, Jodie ^b   Ramsay, Mary E ^c   Whitney, Cynthia G ^d   Mulholland, E Kim ^e   Goldblatt, David ^f   Hombach, Joachim ^g   Kieny, Marie Paule ^g  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g Initiative for Vaccine Research   (Switzerland)

Author keywords

Haemophilus vaccines; Meningococcal vaccines; Pneumococcal vaccines

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; MENINGOCOCCUS VACCINE; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; STREPTOCOCCUS VACCINE;

DEVELOPED COUNTRY; DEVELOPING COUNTRY; DRUG COST; DRUG EFFICACY; DRUG INDICATION; GRAM NEGATIVE INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH PROGRAM; HERD IMMUNITY; HUMAN; IMMUNOGENICITY; INFECTION CONTROL; INFECTION PREVENTION; NEISSERIA MENINGITIDIS; NEISSERIACEAE INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINE PRODUCTION;

CARRIER STATE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 48649087719     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.05.073     Document Type: Review

References (153)

1. Anon. WHO position paper on Haemophilus influenzae type b conjugate vaccines (Replaces WHO position paper on Hib vaccines previously published in the Weekly Epidemiological Record). Wkly Epidemiol Rec 81 47 (2006) 445-452
2. Mpairwe Y. Observations on the nasopharyngeal carriage of Haemophilus influenzae type b in children in Kampala, Uganda. J Hyg (Lond) 68 2 (1970) 337-341
3. Gessner B.D., Sutanto A., Steinhoff M., Soewignjo S., Widjaya A., Nelson C., et al. A population-based survey of Haemophilus influenzae type b nasopharyngeal carriage prevalence in Lombok Island, Indonesia. Pediatr Infect Dis J 17 9 Suppl. (1998) S179-S182
4. Forleo-Neto E., de Oliveira C.F., Maluf E.M., Bataglin C., Araujo J.M., Kunz Jr. L.F., et al. Decreased point prevalence of Haemophilus influenzae type b (Hib) oropharyngeal colonization by mass immunization of Brazilian children less than 5 years old with hib polyribosylribitol phosphate polysaccharide-tetanus toxoid conjugate vaccine in combination with diphtheria-tetanus toxoids-pertussis vaccine. J Infect Dis 180 4 (1999) 1153-1158
5. Bijlmer H.A., Evans N.L., Campbell H., van A.L., Greenwood B.M., Valkenburg H.A., et al. Carriage of Haemophilus influenzae in healthy Gambian children. Trans R Soc Trop Med Hyg 83 6 (1989) 831-835
6. Adegbola R.A., Mulholland E.K., Secka O., Jaffar S., and Greenwood B.M. Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H. influenzae type b among Gambian children. J Infect Dis 177 6 (1998) 1758-1761
7. Coen P.G., Heath P.T., Barbour M.L., and Garnett G.P. Mathematical models of Haemophilus influenzae type b. Epidemiol Infect 120 3 (1998) 281-295
8. Dentinger C.M., Hennessy T.W., Bulkow L.R., Reasonover A.L., Romero-Steiner S., Holder P.F., et al. Immunogenicity and reactogenicity to Haemophilus influenzae type B (Hib) conjugate vaccine among rural Alaska adults. Hum Vaccin 2 1 (2006) 24-28
9. Lapeyssonnie L. La meningite cerebrospinale en Afrique. Bull World Health Organ 28 Suppl. (1963) 3-114
10. Molesworth A.M., Thomson M.C., Connor S.J., Cresswell M.P., Morse A.P., Shears P., et al. Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa. Trans R Soc Trop Med Hyg 96 3 (2002) 242-249
11. Greenwood B. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 93 (1999) 341-353
12. Girard M.P., Preziosi M.P., Aguado M.T., and Kieny M.P. A review of vaccine research and development: meningococcal disease. Vaccine 24 22 (2006) 4692-4700
13. Greenwood B. The changing face of meningococcal disease in West Africa. Epidemiol Infect 135 5 (2007) 703-705
14. EU-IBIS Network. Invasive Neisseria meningitidis in Europe 2006. Health Protection Agency, London; 2007 Sep.
15. Stephens D.S., Greenwood B., and Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369 9580 (2007) 2196-2210
16. Cartwright K.A., Stuart J.M., Jones D.M., and Noah N.D. The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol Infect 99 (1987) 591-601
17. Cartwright K. Meningococcal carriage and disease. In: Cartwright K. (Ed). Meningococcal disease (1995), John Wiley & Sons, Chichester 115-146
18. Yazdankhah S.P., and Caugant D.A. Neisseria meningitidis: an overview of the carriage state. J Med Microbiol 53 Pt 9 (2004) 821-832
19. Trotter C.L., and Greenwood B.M. Meningococcal carriage in the African meningitis belt: a review. Lancet Infect Dis 7 12 (2007) 797-803
20. Anon. Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly Epidemiol Rec 82 12 (2007) 93-104
21. Hausdorff W.P., Bryant J., Paradiso P.R., and Siber G.R. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 30 1 (2000) 100-121
22. Cherian T. WHO expert consultation on serotype composition of pneumococcal conjugate vaccines for use in resource-poor developing countries, 26-27 October 2006, Geneva. Vaccine 25 36 (2007) 6557-6564
23. Okeke I.N., Laxminarayan R., Bhutta Z.A., Duse A.G., Jenkins P., O'Brien T.F., et al. Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infect Dis 5 8 (2005) 481-493
24. Bogaert D., de Groot R., and Hermans P.W. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 4 3 (2004) 144-154
25. O'Brien K.L., and Dagan R. The potential indirect effect of conjugate pneumococcal vaccines. Vaccine 21 17-18 (2003) 1815-1825
26. Mbelle N., Huebner R.E., Wasas A.D., Kimura A., Chang I., and Klugman K.P. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 180 4 (1999) 1171-1176
27. Valles X., Flannery B., Roca A., Mandomando I., Sigauque B., Sanz S., et al. Serotype distribution and antibiotic susceptibility of invasive and nasopharyngeal isolates of Streptococcus pneumoniae among children in rural Mozambique. Trop Med Int Health 11 3 (2006) 358-366
28. Mastro T.D., Nomani N.K., Ishaq Z., Ghafoor A., Shaukat N.F., Esko E., et al. Use of nasopharyngeal isolates of Streptococcus pneumoniae and Haemophilus influenzae from children in Pakistan for surveillance for antimicrobial resistance. Pediatr Infect Dis J 12 10 (1993) 824-830
29. Frederiksen B., and Henrichsen J. Throat carriage of Streptococcus pneumoniae and Streptococcus pyogenes among infants and children in Zambia. J Trop Pediatr 34 3 (1988) 114-117
30. Lankinen K.S., Leinonen M., Tupasi T.E., Haikala R., and Ruutu P. Pneumococci in nasopharyngeal samples from Filipino children with acute respiratory infections. J Clin Microbiol 32 12 (1994) 2948-2952
31. Gratten M., Gratten H., Poli A., Carrad E., Raymer M., and Koki G. Colonisation of Haemophilus influenzae and Streptococcus pneumoniae in the upper respiratory tract of neonates in Papua New Guinea: primary acquisition, duration of carriage, and relationship to carriage in mothers. Biol Neonate 50 2 (1986) 114-120
32. Granat S.M., Mia Z., Ollgren J., Herva E., Das M., Piirainen L., et al. Longitudinal study on pneumococcal carriage during the first year of life in Bangladesh. Pediatr Infect Dis J 26 4 (2007) 319-324
33. Goldblatt D. Conjugate vaccines. Clin Exp Immunol 119 1 (2000) 1-3
34. Bar-Zeev N., and Buttery J.P. Combination conjugate vaccines. Expert Opin Drug Saf 5 3 (2006) 351-360
35. Decker M.D., and Edwards K.M. Haemophilus influenzae type b vaccines: history, choice and comparisons. Pediatr Infect Dis J 17 9 Suppl. (1998) S113-S116
36. Trotter C.L., and Ramsay M.E. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev 31 (2007) 101-107
37. CDC. Revised recommendations of the advisory committee on immunization practices to vaccinate all persons aged 11-18 years with meningococcal conjugate vaccine. MMWR Morb Mortal Wkly Rep 56 31 (2007) 794-795
38. Chief Medical Officer, Chief nursing officer, Chief pharmacist. Planned changes to the routine childhood immunisation programme; 2006. Available from (accessed 7th May 2008) http://www.dh.gov.uk/assetRoot/04/12/81/21/04128121.pdf.
39. LaForce F.M., Konde K., Viviani S., and Preziosi M.P. The Meningitis Vaccine Project. Vaccine 25 S (2007) A97-A100
40. Robbins J.B., Schneerson R., and Gotschlich E.C. A rebuttal: epidemic and endemic meningococcal meningitis in sub-Saharan Africa can be prevented now by routine immunization with group A meningococcal capsular polysaccharide vaccine. Pediatr Infect Dis J 19 10 (2000) 945-953
41. Eskola J., Peltola H., Takala A.K., Kayhty H., Hakulinen M., Karanko V., et al. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy. N Engl J Med 317 12 (1987) 717-722
42. Eskola J., Kayhty H., Takala A.K., Peltola H., Ronnberg P.R., Kela E., et al. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med 323 20 (1990) 1381-1387
43. Black S.B., Shinefield H.R., Fireman B., Hiatt R., Polen M., and Vittinghoff E. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J 10 2 (1991) 97-104
44. Vadheim C.M., Greenberg D.P., Partridge S., Jing J., and Ward J.I. Effectiveness and safety of an Haemophilus influenzae type b conjugate vaccine (PRP-T) in young infants. Kaiser-UCLA Vaccine Study Group. Pediatrics 92 2 (1993) 272-279
45. Booy R., Hodgson S., Carpenter L., Mayon-White R.T., Slack M.P., Macfarlane J.A., et al. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet 344 8919 (1994) 362-366
46. Heath P.T. Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr Infect Dis J 17 9 Suppl. (1998) S117-S122
47. Santosham M., Wolff M., Reid R., Hohenboken M., Bateman M., Goepp J., et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 324 25 (1991) 1767-1772
48. Mulholland K., Hilton S., Adegbola R., Usen S., Oparaugo A., Omosigho C., et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine for prevention of pneumonia and meningitis in Gambian infants. Lancet 349 9060 (1997) 1191-1197
49. Miller E., Salisbury D.M., and Ramsay M.E. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20 (2001) S58-S67
50. Soriano-Gabarro M., Rosenstein N., and LaForce F.M. Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project. J Health Popul Nutr 22 3 (2004) 275-285
51. Hansen J., Black S., Shinefield H., Cherian T., Benson J., Fireman B., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J 25 9 (2006) 779-781
52. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19 3 (2000) 187-195
53. O'Brien K.L., Moulton L.H., Reid R., Weatherholtz R., Oski J., Brown L., et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 362 9381 (2003) 355-361
54. Dagan R., Sikuler-Cohen M., Zamir O., Janco J., Givon-Lavi N., and Fraser D. Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees. Pediatr Infect Dis J 20 10 (2001) 951-958
55. Eskola J., Kilpi T., Palmu A., Jokinen J., Haapakoski J., Herva E., et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 344 6 (2001) 403-409
56. Klugman K.P., Madhi S.A., Huebner R.E., Kohberger R., Mbelle N., and Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 349 14 (2003) 1341-1348
57. Cutts F.T., Zaman S.M., Enwere G., Jaffar S., Levine O.S., Okoko J.B., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365 9465 (2005) 1139-1146
58. Danovaro-Holliday M.C., Garcia S., de Qadros C., and Andrus J.K. Progress in vaccination against Haemophilus influenzae type b in the Americas. PLoS Med 5 4 (2008) e87
59. Shinefield H.R., and Black S. Post-licensure surveillance for Haemophilus influenzae type b invasive disease after use of Haemophilus influenzae type b oligosaccharide CRM197 conjugate vaccine in a large defined United States population: a four-year eight-month follow-up. Pediatr Infect Dis J 14 11 (1995) 978-981
60. Bisgard K.M., Kao A., Leake J., Strebel P.M., Perkins B.A., and Wharton M. Haemophilus influenzae invasive disease in the United States, 1994-1995: near disappearance of a vaccine-preventable childhood disease. Emerg Infect Dis 4 2 (1998) 229-237
61. Wenger J.D. Epidemiology of Haemophilus influenzae type b disease and impact of Haemophilus influenzae type b conjugate vaccines in the United States and Canada. Pediatr Infect Dis J 17 (1998) S132-S136
62. Slack M.P.E., Azzopardi H.J., Hargreaves R.M., and Ramsay M.E. Enhanced surveillance of invasive Haemophilus influenzae disease in England, 1990 to 1996: impact of conjugate vaccines. Pediatr Infect Dis J 17 S9 (1998) S204-S207
63. van A.L., Spanjaard L., van der E.A., Schuurman I., and Dankert J. Effect of nationwide vaccination of 3-month-old infants in The Netherlands with conjugate Haemophilus influenzae type b vaccine: high efficacy and lack of herd immunity. J Pediatr 131 6 (1997) 869-873
64. Dagan R., Fraser D., Roitman M., Slater P., Anis E., Ashkenazi S., et al. Effectiveness of a nationwide infant immunization program against Haemophilus influenzae b. The Israeli Pediatric Bacteremia and Meningitis Group. Vaccine 17 2 (1999) 134-141
65. Jonsdottir K.E., Steingrimsson O., and Olafsson O. Immunisation of infants in Iceland against Haemophilus influenzae type b. Lancet 340 8813 (1992) 252-253
66. Peltola H., Aavitsland P., Hansen K.G., Jonsdottir K.E., Nokleby H., and Romanus V. Perspective: a five-country analysis of the impact of four different Haemophilus influenzae type b conjugates and vaccination strategies in Scandinavia. J Infect Dis 179 1 (1999) 223-229
67. Garpenholt O., Hugosson S., Fredlund H., Giesecke J., and Olcen P. Invasive disease due to Haemophilus influenzae type b during the first six years of general vaccination of Swedish children. Acta Paediatr 89 4 (2000) 471-474
68. Peltola H., Salo E., and Saxen H. Incidence of Haemophilus influenzae type b meningitis during 18 years of vaccine use: observational study using routine hospital data. BMJ 330 7481 (2005) 18-19
69. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 13 2 (2000) 302-317
70. Singleton R., Bulkow L.R., Levine O.S., Butler J.C., Hennessy T.W., and Parkinson A. Experience with the prevention of invasive Haemophilus influenzae type b disease by vaccination in Alaska: the impact of persistent oropharyngeal carriage. J Pediatr 137 3 (2000) 313-320
71. Harrison L.H., Tajkowski C., Croll J., Reid R., Hu D., Brenneman G., et al. Postlicensure effectiveness of the Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer-membrane protein complex conjugate vaccine among Navajo children. J Pediatr 125 4 (1994) 571-576
72. Markey P., Krause V., Boslego J.W., Coplan P.M., Dargan J.M., and Kaplan K.M. The effectiveness of Haemophilus influenzae type b conjugate vaccines in a high risk population measured using immunization register data. Epidemiol Infect 126 1 (2001) 31-36
73. Adegbola R.A., Secka O., Lahai G., Lloyd-Evans N., Njie A., Usen S., et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 366 9480 (2005) 144-150
74. Martin M., Casellas J.M., Madhi S.A., Urquhart T.J., Delport S.D., Ferrero F., et al. Impact of Haemophilus influenzae type b conjugate vaccine in South Africa and Argentina. Pediatr Infect Dis J 23 9 (2004) 842-847
75. von Gottberg A., de Gouveia L., Madhi S.A., du Plessis M., Quan V., Soma K., et al. Impact of conjugate Haemophilus influenzae type b (Hib) vaccine introduction in South Africa. Bull World Health Organ 84 10 (2006) 811-818
76. Daza P., Banda R., Misoya K., Katsulukuta A., Gessner B.D., Katsande R., et al. The impact of routine infant immunization with Haemophilus influenzae type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus prevalence. Vaccine 24 37-39 (2006) 6232-6239
77. Cowgill K.D., Ndiritu M., Nyiro J., Slack M.P., Chiphatsi S., Ismail A., et al. Effectiveness of Haemophilus influenzae type b Conjugate vaccine introduction into routine childhood immunization in Kenya. JAMA 296 6 (2006) 671-678
78. Lagos R., Levine O.S., Avendano A., Horwitz I., and Levine M.M. The introduction of routine Haemophilus influenzae type b conjugate vaccine in Chile: a framework for evaluating new vaccines in newly industrializing countries. Pediatr Infect Dis J 17 9 Suppl. (1998) S139-S148
79. de Andrade A.L., de Andrade J.G., Martelli C.M., Silva S.A., de Oliveira R.M., Costa M.S., et al. Effectiveness of Haemophilus influenzae b conjugate vaccine on childhood pneumonia: a case-control study in Brazil. Int J Epidemiol 33 1 (2004) 173-181
80. Wenger J.D., DiFabio J., Landaverde J.M., Levine O.S., and Gaafar T. Introduction of Hib conjugate vaccines in the non-industrialized world: experience in four 'newly adopting' countries. Vaccine 18 7-8 (1999) 736-742
81. Lucher L.A., Singleton R., Parkinson A.J., and Butler J.C. The challenge of ongoing Haemophilus influenzae type B carriage and transmission in Alaska. Alaska Med 41 3 (1999) 61-68
82. Trotter C.L., Ramsay M.E., and Slack M.P. Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. Commun Dis Public Health 6 1 (2003) 55-58
83. Farrington C.P. Estimation of vaccine effectiveness using the screening method. Int J Epidemiol 22 5 (1993) 742-746
84. Ramsay M.E., McVernon J., Andrews N.J., Heath P.T., and Slack M.P. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 188 (2003) 481-485
85. Trotter C.L., McVernon J., Andrews N.J., Burrage M., and Ramsay M.E. Antibody to Haemophilus influenzae type b after routine and catch-up vaccination. Lancet 361 9368 (2003) 1523-1524
86. McVernon J., Trotter C.L., Slack M.P., and Ramsay M.E. Trends in Haemophilus influenzae type b infections in adults in England and Wales: surveillance study. BMJ 329 7467 (2004) 655-658
87. McVernon J., Andrews N., Slack M.P., and Ramsay M.E. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 361 9368 (2003) 1521-1523
88. Fitzgerald M., Canny M., and O'Flanagan D. Vaccination catch-up campaign in response to recent increase in Hib infection in Ireland. Euro Surveill 10 9 (2005) E050929
89. Rijkers G.T., Vermeer-de Bondt P.E., Spanjaard L., Breukels M.A., and Sanders E.A. Return of Haemophilus influenzae type b infections. Lancet 361 9368 (2003) 1563-1564
90. Howie S.R., Antonio M., Akisanya A., Sambou S., Hakeem I., Secka O., et al. Re-emergence of Haemophilus influenzae type b (Hib) disease in The Gambia following successful elimination with conjugate Hib vaccine. Vaccine 25 34 (2007) 6305-6309
91. Ramsay M.E., Andrews N., Kaczmarksi E.B., and Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 357 (2001) 195-196
92. Bose A., Coen P., Viner R., and Booy R. Effectiveness of meningococcal C conjugate vaccine in teenagers in England. Lancet 361 (2003) 675-676
93. Trotter C.L., Andrews N.J., Kaczmarski E.B., Miller E., and Ramsay M.E. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364 9431 (2004) 365-367
94. Larrauri A., Cano R., Garcia M., and Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 23 32 (2005) 4097-4100
95. De W.P., Deceuninck G., Boulianne N., and De S.G. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA 292 20 (2004) 2491-2494
96. Trotter C.L., Chandra M., Cano R., Larrauri A., Ramsay M.E., Brehony C., et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 31 (2007) 27-36
97. de Greeff S.C., de Melker H.E., Spanjaard L., Schouls L.M., and van D.A. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 25 1 (2006) 79-80
98. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348 18 (2003) 1737-1746
99. CDC. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. MMWR Morb Mortal Wkly Rep 54 36 (2005) 893-897
100. Kaplan S.L., Mason Jr. E.O., Wald E.R., Schutze G.E., Bradley J.S., Tan T.Q., et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 113 3 Pt 1 (2004) 443-449
101. Kellner J.D., Church D.L., MacDonald J., Tyrrell G.J., and Scheifele D. Progress in the prevention of pneumococcal infection. CMAJ 173 10 (2005) 1149-1151
102. Roche P., Krause V., and Cook H. Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell 32 1 (2008) 18-30
103. Mahon B.E., Hsu K., Karumuri S., Kaplan S.L., Mason Jr. E.O., and Pelton S.I. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. Vaccine 24 14 (2006) 2514-2520
104. Whitney C.G., Pilishvili T., Farley M.M., Schaffner W., Craig A.S., Lynfield R., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368 9546 (2006) 1495-1502
105. Poehling K.A., Szilagyi P.G., Grijalva C.G., Martin S.W., LaFleur B., Mitchel E., et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 119 4 (2007) 707-715
106. Grijalva C.G., Poehling K.A., Nuorti J.P., Zhu Y., Martin S.W., Edwards K.M., et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 118 3 (2006) 865-873
107. Grijalva C.G., Nuorti J.P., Arbogast P.G., Martin S.W., Edwards K.M., and Griffin M.R. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369 9568 (2007) 1179-1186
108. Takala A.K., Eskola J., Leinonen M., Kayhty H., Nissinen A., Pekkanen E., et al. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with a Hib conjugate vaccine. J Infect Dis 164 (1991) 982-986
109. Mohle-Boetani J.C., Ajello G., Breneman E., Deaver K.A., Harvey C., Plikaytis B.D., et al. Carriage of Haemophilus influenzae type b in children after widespread vaccination with conjugate Haemophilus influenzae type b vaccines. Pediatr Infect Dis J 12 7 (1993) 589-593
110. Rushdy A., Ramsay M., Heath P.T., Azzopardi H.J., and Slack M.P. Infant Hib vaccination and herd immunity. J Pediatr 134 2 (1999) 253-254
111. Barbour M.L., Mayon-White R.T., Coles C., Crook D.M.W., and Moxon E.R. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J Infect Dis 171 (1995) 93-98
112. Murphy T.V., Pastor P., Medley F., Osterholm M.T., and Granoff D.M. Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine. J Pediatr 122 4 (1993) 517-523
113. Maiden M.C.J., Stuart J.M., and on behalf of the UK Meningococcal Carriage Group. Carriage of serogroup C meningococci one year after meningococcal C conjugate polysaccharide vaccination. Lancet 359 (2002) 1829-1830
114. Ramsay M.E., Andrews N.J., Trotter C.L., Kaczmarski E.B., and Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 326 7385 (2003) 365-366
115. Trotter C.L., Gay N.J., and Edmunds W.J. The natural history of meningococcal carriage and disease. Epidemiol Infect 134 3 (2006) 556-566
116. Dagan R., Melamed R., Muallem M., Piglansky L., Greenberg D., Abramson O., et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 174 6 (1996) 1271-1278
117. Dagan R., Muallem M., Melamed R., Leroy O., and Yagupsky P. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatr Infect Dis J 16 11 (1997) 1060-1064
118. Dagan R., Givon-Lavi N., Zamir O., Sikuler-Cohen M., Guy L., Janco J., et al. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis 185 7 (2002) 927-936
119. O'Brien K.L., Millar E.V., Zell E.R., Bronsdon M., Weatherholtz R., Reid R., et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children ina community-randomized trial. J Infect Dis 196 (2007) 1211-1220
120. Ghaffar F., Barton T., Lozano J., Muniz L.S., Hicks P., Gan V., et al. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis 39 7 (2004) 930-938
121. Pelton S.I., Loughlin A.M., and Marchant C.D. Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates. Pediatr Infect Dis J 23 11 (2004) 1015-1022
122. Jones V.F., Harrison C., Stout G.G., and Hopkins J. Nasopharyngeal colonization with heptavalent pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae with prolonged vaccine dosing intervals. Pediatr Infect Dis J 24 11 (2005) 969-973
123. Huang S.S., Platt R., Rifas-Shiman S.L., Pelton S.I., Goldmann D., and Finkelstein J.A. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 116 3 (2005) e408-e413
124. Hammitt L.L., Bruden D.L., Butler J.C., Baggett H.C., Hurlburt D.A., Reasonover A., et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis 193 11 (2006) 1487-1494
125. Hennessy T.W., Singleton R.J., Bulkow L.R., Bruden D.L., Hurlburt D.A., Parks D., et al. Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska natives: progress towards elimination of a health disparity. Vaccine 23 48-49 (2005) 5464-5473
126. McBean A.M., Park Y.T., Caldwell D., and Yu X. Declining invasive pneumococcal disease in the U.S. elderly. Vaccine 23 48-49 (2005) 5641-5645
127. Poehling K.A., Talbot T.R., Griffin M.R., Craig A.S., Whitney C.G., Zell E., et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 295 14 (2006) 1668-1674
128. Albrich W.C., Madhi S.A., Lafond K.E., and Klugman K.P. Herd immunity after pneumococcal conjugate vaccination. Lancet 370 9583 (2007) 218-219
129. Gallo G., Ciofi degli Atti M.L., Cerquetti M., Piovesan C., Tozzi A.E., and Salmaso S. Impact of a regional Hib vaccination programme in Italy. Vaccine 20 7-8 (2002) 993-995
130. Trotter C.L., Gay N.J., and Edmunds W.J. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol 162 1 (2005) 89-100
131. Fairley C.K., Begg N., Borrow R., Fox A.J., Jones D.M., and Cartwright K. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and imunogenicity in UK infants. J Infect Dis 174 (1996) 1360-1363
132. Richmond P., Borrow R., Miller E., Clark S., Sadler F., Fox A., et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 179 6 (1999) 1569-1572
133. Borrow R., Goldblatt D., Finn A., Southern J., Ashton L., Andrews N., et al. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom. Infect Immun 71 10 (2003) 5549-5555
134. Southern J., Crowley-Luke A., Borrow R., Andrews N., and Miller E. Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine. Vaccine 24 2 (2006) 215-219
135. Chippaux J.P., Garba A., Ethevenaux C., Campagne G., de C.F., Djibo S., et al. Immunogenicity, safety, and memory of different schedules of Neisseria meningitidis A/C-diphtheria toxoid conjugate vaccine in infants in Niger. Vaccine 22 25-26 (2004) 3303-3311
136. Esposito S., Lizioli A., Lastrico A., Begliatti E., Rognoni A., Tagliabue C., et al. Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age. Respir Res 8 1 (2007) 12
137. Goldblatt D., Southern J., Ashton L., Richmond P., Burbidge P., Tasevska J., et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 25 4 (2006) 312-319
138. Southern J., McVernon J., Gelb D., Andrews N., Morris R., Crowley-Luke A., et al. Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infancy. Clin Vac Immunol 14 10 (2007) 1328-1333
139. Esposito S., Pugni L., Bosis S., Proto A., Cesati L., Bianchi C., et al. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants. Vaccine 23 14 (2005) 1703-1708
140. Kayhty H., Ahman H., Eriksson K., Sorberg M., and Nilsson L. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr Infect Dis J 24 2 (2005) 108-114
141. Goldblatt D., Hussain M., Andrews N., Ashton L., Virta C., Melegaro A., et al. Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. J Infect Dis 192 3 (2005) 387-393
142. Millar E.V., O'Brien K.L., Watt J.P., Bronsdon M.A., Dallas J., Whitney C.G., et al. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population. Clin Infect Dis 43 1 (2006) 8-15
143. Lipsitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis 5 3 (1999) 336-345
144. Hicks L.A., Harrison L.H., Flannery B., Hadler J.L., Schaffner W., Craig A.S., et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 196 9 (2007) 1346-1354
145. Byington C.L., Samore M.H., Stoddard G.J., Barlow S., Daly J., Korgenski K., et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin Infect Dis 41 1 (2005) 21-29
146. Singleton R.J., Hennessy T.W., Bulkow L.R., Hammitt L.L., Zulz T., Hurlburt D.A., et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297 16 (2007) 1784-1792
147. Madhi S.A., Adrian P., Kuwanda L., Jassat W., Jones S., Little T., et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 25 13 (2007) 2451-2457
148. Obaro S.K., Enwere G.C., Deloria M., Jaffar S., Goldblatt D., Brainsby K., et al. Safety and immunogenicity of pneumococcal conjugate vaccine in combination with diphtheria, tetanus toxoid, pertussis and Haemophilus influenzae type b conjugate vaccine. Pediatr Infect Dis J 21 10 (2002) 940-947
149. Rennels M.B., Edwards K.M., Keyserling H.L., Reisinger K.S., Hogerman D.A., Madore D.V., et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 101 4 Pt 1 (1998) 604-611
150. O'Brien K.L., Moisi J., Moulton L.H., Madore D., Eick A., Reid R., et al. Predictors of pneumococcal conjugate vaccine immunogenicity among infants and toddlers in an American Indian PnCRM7 efficacy trial. J Infect Dis 196 1 (2007) 104-114
151. Kayhty H., Auranen K., Nohynek H., Dagan R., and Makela H. Nasopharyngeal colonization: a target for pneumococcal vaccination. Expert Rev Vac 5 5 (2006) 651-667
152. Barzilay E.J., O'Brien K.L., Kwok Y.S., Hoekstra R.M., Zell E.R., Reid R., et al. Could a single dose of pneumococcal conjugate vaccine in children be effective? Modeling the optimal age of vaccination. Vaccine 24 7 (2006) 904-913
153. Mulholland E.K., Smith L., Carneiro I., Becher H., and Lehmann D. Equity and child-survival strategies. Bull WHO 86 5 (2008) 399-407